Grant: Discovery Grants Program - Individual
Université Laval
$47,000.00
Effect of membrane fluidity on brain receptors and transporters
EF 2015-16
Résumé
The objective of this research program in neuropharmacology is to investigate the effect of membrane composition/fluidity on neurotransmitter function in the brain. The hypothesis is that changes of membrane composition and/or fluidity will have effects specific for certain receptors and transporters and specific for certain brain regions. We propose to investigate in vitro a dose-response of agents that rigidify membranes (cholesteryl hemisuccinate and stearic acid) compared to agents that fluidify membranes (linoleic acid, L-alpha-phosphatidylcholine and DHA, omega-3, a widely used nutritional supplement) in bovine brain membranes. We will investigate how fluidity changes affect dopamine (D2), adenosine (A2A), GABAA, serotonin (5-HT1A, 5-HT2A) glutamate (NMDA, mGluR5) receptors compared to the dopamine transporter DAT. The frontal cortex, the hippocampus and the striatum representing a range from more fluid to more rigid brain membranes will be studied. Fluidity will be measured with fluorescent probes. Total membrane receptors and transporters will be measured by Western blot and their surface levels with binding of specific radioligands. The functional changes will be measured with coupling to second messengers and key signaling proteins. In vivo in rats a condition presenting a more rigid membrane will be investigated with old rat whereas more fluid membranes will be investigated by reducing cholesterol with a chronic statin drug treatment, DHA treatment or plasmalogen (to increase DHA levels) treatment. For in vivo experiments we will also measure by in situ hydridization mRNA of these receptors to assess their synthesis. We expect that small membrane changes will significantly affect the membrane receptor investigated and that this has important physiological consequences. Compounds affecting membranes could be administered (or a diet designed) to enhance efficacy of drug treatments targeting these receptors and transporters for successful aging.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
171354-2011
Name nom
DiPaoloChênevert, Thérèse
Department département
Pharmacie, Faculté de
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2011
Award amount
47000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
5
Nb partie
5
Application title
Effect of membrane fluidity on brain receptors and transporters
Keyword
NSERC
Application summary
The objective of this research program in neuropharmacology is to investigate the effect of membrane composition/fluidity on neurotransmitter function in the brain. The hypothesis is that changes of membrane composition and/or fluidity will have effects specific for certain receptors and transporters and specific for certain brain regions. We propose to investigate in vitro a dose-response of agents that rigidify membranes (cholesteryl hemisuccinate and stearic acid) compared to agents that fluidify membranes (linoleic acid, L-alpha-phosphatidylcholine and DHA, omega-3, a widely used nutritional supplement) in bovine brain membranes. We will investigate how fluidity changes affect dopamine (D2), adenosine (A2A), GABAA, serotonin (5-HT1A, 5-HT2A) glutamate (NMDA, mGluR5) receptors compared to the dopamine transporter DAT. The frontal cortex, the hippocampus and the striatum representing a range from more fluid to more rigid brain membranes will be studied. Fluidity will be measured with fluorescent probes. Total membrane receptors and transporters will be measured by Western blot and their surface levels with binding of specific radioligands. The functional changes will be measured with coupling to second messengers and key signaling proteins. In vivo in rats a condition presenting a more rigid membrane will be investigated with old rat whereas more fluid membranes will be investigated by reducing cholesterol with a chronic statin drug treatment, DHA treatment or plasmalogen (to increase DHA levels) treatment. For in vivo experiments we will also measure by in situ hydridization mRNA of these receptors to assess their synthesis. We expect that small membrane changes will significantly affect the membrane receptor investigated and that this has important physiological consequences. Compounds affecting membranes could be administered (or a diet designed) to enhance efficacy of drug treatments targeting these receptors and transporters for successful aging.